Journal of Pharmaceutical Chemistry & Chemical Science

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Commentary - Journal of Pharmaceutical Chemistry & Chemical Science (2022) Volume 6, Issue 6

Detection, visualization, biomarkers and anti-tumor action of monoclonal antibodies in lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite increasing efforts toward early detection through screening of at-risk populations, the majority of lung cancer patients are still diagnosed at an advanced stage. Lung cancer is an aggressive disease and its conventional treatments have been far from successful. There is a strong need for new and better approaches to improve survival, symptom control, and quality of life. A challenge in treating lung cancer is the lack of early diagnosis. New options in targeted therapy and immunotherapy are shifting lung cancer treatment towards a more individualized therapeutic approach that has a profound impact on the clinical course and outcome of the disease. We focused on known mechanisms of action, current clinical applications in cancer therapy, and resistance mechanisms to monoclonal antibody therapy. We describe how monoclonal antibody-based strategies have evolved and some of the current combination therapies to enhance anti-tumor immune responses by targeting immune cells instead of tumor antigens.

Author(s): Dawei Hirsch

Abstract Full Text PDF

Get the App

Vizag Tech Summit